|
Indirect assessment of tumor-infiltrating lymphocyte activity in serum for predicting outcome in patients with glioblastoma treated with immunotherapy in the recurrent setting. |
|
|
Employment - Nordic Bioscience |
|
|
Research Funding - Danish Cancer Society (Inst) |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Stock and Other Ownership Interests - IO Biotech |
Honoraria - BMS; IO Biotech; MSD; Novartis; Novo Nordisk; Pierre Fabre; Sanofi/Aventis; TILT Biotherapeutics |
Consulting or Advisory Role - IO Biotech; MSD; Novartis; Novo Nordisk; Pierre Fabre; TILT Biotherapeutics |
Research Funding - Adaptimmune (Inst); Bristol-Myers Squibb (Inst); IO Biotech (Inst); Lytix Biopharma (Inst); TILT Biotherapeutics (Inst) |
Travel, Accommodations, Expenses - MSD; Novartis; Pfizer |
|
|
Honoraria - Bayer; Novartis; Pfizer |
Consulting or Advisory Role - Bayer; Pfizer |
Research Funding - BMS (Inst); GlaxoSmithKline (Inst); Incyte (Inst); Lilly (Inst); Pfizer (Inst); Roche (Inst) |
|
|
Employment - Nordic Bioscience |
Stock and Other Ownership Interests - Nordic Bioscience |